



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/664,725

09/18/2003

Manabu Nakatani

01-1395

4358

28501

7590

02/02/2010

MICHAEL P. MORRIS

BOEHRINGER INGELHEIM USA CORPORATION

900 RIDGEBURY ROAD

P. O. BOX 368

RIDGEFIELD, CT 06877-0368

EXAMINER

HELM, CARALYNNE E

ART UNIT

PAPER NUMBER

1615

NOTIFICATION DATE

DELIVERY MODE

02/02/2010

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTO.e-Office.rdg@boehringer-ingelheim.com

<p align="center">Advisory Action Before the Filing of an Appeal Brief</p>	<p>Application No. 10/664,725</p>	<p>Applicant(s) NAKATANI ET AL.</p>	
	<p>Examiner CARALYNNE HELM</p>	<p>Art Unit 1615</p>	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 13 January 2010 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. ☒ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

- a) ☒ The period for reply expires 3 months from the mailing date of the final rejection.
b) ☐ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. ☒ The Notice of Appeal was filed on 13 January 2010. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. ☐ The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
(a) ☐ They raise new issues that would require further consideration and/or search (see NOTE below);
(b) ☐ They raise the issue of new matter (see NOTE below);
(c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: _____. (See 37 CFR 1.116 and 41.33(a)).

4. ☐ The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5. ☐ Applicant's reply has overcome the following rejection(s): _____.
6. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
7. ☐ For purposes of appeal, the proposed amendment(s): a) ☐ will not be entered, or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed: _____.
Claim(s) objected to: _____.
Claim(s) rejected: _____.
Claim(s) withdrawn from consideration: _____.

AFFIDAVIT OR OTHER EVIDENCE

8. ☐ The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
9. ☐ The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. ☒ The request for reconsideration has been considered but does NOT place the application in condition for allowance because:
See Continuation Sheet.
12. ☐ Note the attached Information *Disclosure Statement*(s). (PTO/SB/08) Paper No(s). _____.
13. ☐ Other: _____.

/Caralynne Helm/
Examiner, Art Unit 1615

/Robert A. Wax/
Supervisory Patent Examiner, Art Unit 1615

Continuation of 11. does NOT place the application in condition for allowance because: Applicants' arguments are not persuasive. Applicants argue that the secondary references do not relate to telmisartan and, more specifically, that there was no reason why the invention of Gaviraghi et al. should be modified. The secondary references provide teachings of conventional pharmaceutical production methodologies and ingredients that are references in Gaviraghi et al., but not expounded upon in this reference. Gaviraghi et al. teach binders, in general, being used in the preparation of their solid oral dosage form (see page 8 line 2). They go on to provide hydroxypropylmethyl cellulose, gelatin, and povidone as examples of those that can be utilized. Doi et al. also teach a solid oral dosage form that utilizes a binder and names gelatin and polyvinylpyrrolidone (povidone), also discussed by Gaviraghi et al. as well as names others that can be used in the same capacity which include Pluronic F68 (poloxamer 188). One of ordinary skill in the art would have had good reason to substitute one known hydrophilic binder for another (as equivalent elements) and have a reasonable expectation of success. Further, there is no evidence of record to demonstrate that an unexpected result occurs when employing poloxamer 188 as opposed to polyvinylpyrrolidone as a binder in the composition. Thus the substitution of poloxamer 188 for polyvinylpyrrolidone as a binder in the invention of Gaviraghi et al. as known hydrophilic binders used in solid oral dosage forms would have been obvious. Frisbee et al. is relied upon as a purely evidentiary reference to provide the molecular weight of poloxamer 188 that was known at the time of the invention. Raghunathan teaches solid oral dosage forms with an antihypertensive and diuretic in a unitary dosage form, as is claimed by the instant application. For this reason their teachings are applicable to those of the instant application. Curatolo et al. teach conventional methods of preparing solid dosage forms which are generally taught as applicable to the invention of Gaviraghi et al. (see page 9 line 28-page 10 line 1). Therefore the combination of references as cited in the rejections was reasonable, would have been obvious to one of ordinary skill in the art, and had a reasonable expectation of success.